Asthma News and Research

RSS

Asthma is a common inflammatory disease affecting the airways that leads to shortness of breath, coughing and wheezing. Symptoms range from mild to severe but are generally manageable with appropriate treatment.

Nuvo Research's PENNSAID now available in U.S. pharmacies

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.

27 Apr 2010

Medication-free home ventilation system designed to remove allergens

According to a recent report by USA Today, due to 2010's unusually cold winter temperatures, allergy sufferers are now poised to experience the worst pollen season in years, with pollen counts skyrocketing and sufferers hiding indoors to avoid exposure. Yet as allergens creep indoors, sufferers continue to cough, sneeze and seek relief. With the introduction of EZ Breathe, a new innovative home ventilation system designed to remove allergens and reduce indoor concentrations of pollen, allergy sufferers now have a medication-free solution.

27 Apr 2010

Researchers to commence enrolling participants in National Children's Study

After years of planning, UT Southwestern Medical Center researchers are ready to begin enrolling participants in the National Children's Study, which will examine the effects of environmental and genetic factors on child and adult health.

27 Apr 2010

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

27 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

New FDA approved Landon Medical PC-60C2 Finger Pulse Oximeter introduced for home use

PulseOximetersDIRECT.com, the leading online retailer of portable Pulse Oximeter products introduces today the new FDA approved Landon Medical PC-60C2 Finger Pulse Oximeter for home use.

26 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Covidien launches EXALGO Extended-Release Tablets in the US

Covidien, a leading global provider of healthcare products, today introduced EXALGO™ (hydromorphone HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone treatment available in the United States. This proven therapy, combined with an innovative delivery system, provides opioid-tolerant patients suffering from moderate-to-severe chronic pain relief for 24 hours per dose.

26 Apr 2010

Nycomed, Merck enter co-promotion agreement for Daxas in Canada and Europe

Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas® in the United Kingdom.

26 Apr 2010

Spring fever not an official medical condition

In the season of ducklings, blooming dogwoods and open-toed sandals, some people are struck with a mysterious malady - spring fever.

24 Apr 2010

Myths and facts about pediatric cancer

"Your child has cancer." They are words every parent can't imagine hearing.

24 Apr 2010

More tips to protect lungs on elevated-ozone days

It's a harmless-looking pale blue gas, a relative of the oxygen molecule that sustains life. In the upper atmosphere, a layer of it protects us from the sun's harmful rays.

23 Apr 2010

Long-term monitoring of young leukaemia survivors necessary to identify declining lung health: Researchers

Children who have survived leukaemia may need to have regular monitoring to ensure their lungs remain healthy if they had a bone marrow transplantation during their treatment, US scientists have said.

23 Apr 2010

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted it patent number GB2460597 titled "N,N-Disubstituted aminoalkylBiPhenyl Antagonists OF Prostaglandin d2 RECEPTORS."

23 Apr 2010

Los Angeles slum housing health crisis

Over three hundred community members, stakeholders, and public health workers joined Los Angeles County Supervisor Mark Ridley-Thomas for a People's Hearing on Slum Housing and the unveiling of a position paper documenting the health crisis related to slum housing in Los Angeles.

22 Apr 2010

Report highlights 11 key categories of diseases, health consequences that occur due to climate change

A report released today by a federal working group highlights 11 key categories of diseases and other health consequences that are occurring or will occur due to climate change. The report, A Human Health Perspective on Climate Change, provides a starting point for coordination of federal research to better understand climate's impact on human health.

22 Apr 2010

Ozone and primary pollutants from traffic increase asthma-related emergency department visits in children

Both ozone and primary pollutants from traffic substantially increase asthma-related emergency department visits in children, especially during the warm season, according to researchers from the Department of Environmental Health at the Rollins School of Public Health at Emory University in Atlanta.

22 Apr 2010

Children born very early have abnormal lung function: U.K. researchers

More than half of children who were born very early—at 25 weeks or less (normal gestation is around 40 weeks)— have abnormal lung function and are twice as likely as their full-term peers to have a diagnosis of asthma, according to U.K. researchers, who followed a national cohort of extremely preterm infants to age 11.

22 Apr 2010

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.

22 Apr 2010

Roche's progress of RG7348 into Phase I clinical trial triggers $6.5M milestone payment to Ligand

Ligand Pharmaceuticals Incorporated today announced that it earned a $6.5 million payment from Roche as a result of Roche progressing RG7348 into a Phase I clinical trial for the treatment of hepatitis C viral (HCV) infection. The milestone payment arises from a 2008 collaboration and license agreement between Roche and Metabasis Therapeutics, Inc.

21 Apr 2010

Asthma News and Research

Further Reading

Nuvo Research's PENNSAID now available in U.S. pharmacies

Medication-free home ventilation system designed to remove allergens

Researchers to commence enrolling participants in National Children's Study

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

New FDA approved Landon Medical PC-60C2 Finger Pulse Oximeter introduced for home use

Covidien introduces PENNSAID to the U.S. market

Covidien launches EXALGO Extended-Release Tablets in the US

Nycomed, Merck enter co-promotion agreement for Daxas in Canada and Europe

Spring fever not an official medical condition

Myths and facts about pediatric cancer

More tips to protect lungs on elevated-ozone days

Long-term monitoring of young leukaemia survivors necessary to identify declining lung health: Researchers

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Los Angeles slum housing health crisis

Report highlights 11 key categories of diseases, health consequences that occur due to climate change

Ozone and primary pollutants from traffic increase asthma-related emergency department visits in children

Children born very early have abnormal lung function: U.K. researchers

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Roche's progress of RG7348 into Phase I clinical trial triggers $6.5M milestone payment to Ligand

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News